Adlai Nortye Announces First Patient Dosed in Randomized Phase Ii Clinical Trial of Palupiprant for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
Adlai Nortye Ltd. announced that the first patient was dosed in the Phase II clinical trial known as ARTEMIS . This clinical study evaluates palupiprant , a small molecule prostaglandin E receptor 4 ...